Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2016
Accounting Basis: International Financial Reporting Standards (IFRS)
GSK operates in three primary business segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The 2016 reporting period reflects the first full year of operations following the 2015 transaction with Novartis, which involved the sale of GSK's Oncology business and the acquisition of Novartis's Vaccines business and the creation of a Consumer Healthcare Joint Venture.
Key Financial Metrics
| Metric | 2016 Value | 2015 Value | Change (AER) | Change (CER) |
|---|---|---|---|---|
| Turnover | £27,889 million | £23,923 million | +17% | +6% |
| Total Operating Profit | £2,598 million | £10,322 million | -75% | N/A |
| Core Operating Profit | £7,771 million | £5,729 million | +36% | +14% |
| Profit After Taxation (Total) | £1,062 million | £8,372 million | -87% | N/A |
| Core Profit After Taxation | £5,615 million | £4,098 million | +37% | +12% |
| Earnings Per Share (Total) | 18.8p | 174.3p | -89% | N/A |
| Core Earnings Per Share | 102.4p | 75.7p | +35% | +12% |
| Free Cash Flow | £3.1 billion | Small outflow | Significant Improvement | N/A |
| Net Debt | £13.8 billion | £10.7 billion | +29% | N/A |
Note: AER = Actual Exchange Rates; CER = Constant Exchange Rates. Total results include significant non-operational items, while Core results exclude these to reflect underlying operational performance.
Material Changes vs. Prior Period
- Revenue Growth: Turnover increased 17% at actual rates (6% CER) driven by growth across all three segments. Pharmaceuticals grew 14% (3% CER), Vaccines grew 26% (14% CER), and Consumer Healthcare grew 19% (9% CER).
- Profitability Volatility: Total operating profit and EPS declined sharply compared to 2015. This was primarily due to the £9.2 billion profit on the disposal of the Oncology business recorded in 2015, which is not present in 2016.
- Core Performance: Excluding one-off items, Core Operating Profit rose 36% (14% CER) and Core EPS rose 35% (12% CER), indicating strong underlying operational leverage and margin improvement.
- Non-Core Charges: 2016 total results were impacted by £3.9 billion in transaction-related adjustments, primarily remeasurement charges for contingent consideration liabilities (ViiV Healthcare and Consumer Healthcare put options) and major restructuring costs of £970 million.
- Product Mix: New product sales (Pharmaceuticals and Vaccines) reached £4.45 billion, offsetting declines in established products like Seretide/Advair due to generic competition.
Guidance, Outlook, and Risks
2017 Guidance
Management provided conditional guidance for 2017 Core EPS growth based on the timing of generic competition for Advair in the US:
- Scenario A (No Generic in 2017): Core EPS growth of 5-7% at CER, assuming a 15-20% decline in US Advair sales.
- Scenario B (Mid-Year Generic): Core EPS flat to a slight decline at CER, assuming US Advair sales of approximately £1 billion.
Management stated they cannot provide guidance for Total Results due to the unpredictability of fair value movements on contingent consideration and put options.
Principal Risks
- Intellectual Property: Expiration of patents for key products (e.g., Seretide/Advair) leading to generic competition and sales erosion.
- Regulatory and Legal: Ongoing litigation, including product liability and anti-bribery/corruption (ABAC) investigations (US inquiry resolved in 2016; UK inquiry ongoing).
- Financial Contingencies: Significant liabilities for contingent consideration (approx. £5.9 billion at year-end) subject to remeasurement based on sales performance and exchange rates.
- Supply Chain: Risks related to single-source suppliers and manufacturing compliance (cGMP).
Investor Verification Checklist
- Advair Generic Timeline: Verify the actual launch date of generic Advair in the US to determine which 2017 EPS guidance scenario applies.
- Contingent Consideration Liability: Monitor the fair value of the £5.9 billion liability (primarily to Shionogi for ViiV Healthcare) as it significantly impacts Total Results and cash flow.
- Core vs. Total Reconciliation: Scrutinize the reconciliation between Total and Core results, specifically the £3.9 billion in transaction-related charges, to understand the divergence from GAAP/IFRS earnings.
- ABAC Investigations: Track the status of the ongoing UK anti-bribery and corruption inquiry.
- Restructuring Progress: Confirm the delivery of the remaining £200 million in annual savings from the integration and restructuring program.